N/A N=22 Combination Therapy to Treat Sleep Apnea
Sleep Apnea, Obstructive
Primary: Model Prediction of Absence/Presence of OSA: Ventilation That Causes an Arousal From Sleep (Varousal) — 5.7; 5.2 L/min — p=0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=12 Sleep Apnea Treatment With Expiratory Resistance(Provent™)
Sleep Apnea, Obstructive
Primary: Change in AHI — 45; -15.8 events/h
N/A N=104 Lifestyle Modification Program to Treat Obstructive Sleep Apnea Patients
Obstructive Sleep Apnea
Primary: Apnea-hypopnea Index (AHI) at One Year — 35.3; 39.6 events per hour
N/A N=164 Positive Pressure Treatment of Obstructive Sleep Apnea
Obstructive Sleep Apnea
Primary: Apnea-Hypopnea Index — 6.09; 3.54; 3.24; 1.26 events/hour — p=0.3
Phase 3 N=240 Effect of Self-Management on Improving Sleep Apnea Outcomes
Sleep Apnea Syndromes
Primary: CPAP Adherence — 2.8; 3.9 hours per night — p=0.001
N/A N=39 Effective Treatment of Sleep Apnea in Prediabetes to Reduce Cardiometabolic Risk
Diabetes · Sleep Apnea
Primary: Change From Baseline in Area Under the Curve (AUC) Glucose at Week 2 — -794.2; 482.7 (mg/dL)*min — p=0.03
N/A N=34 Positive Airway Pressure Program
Sleep Apnea, Obstructive
Primary: Participant Providing Feedback — 26 Participants
N/A N=15 The Effects of Trazodone on Sleep Apnea Severity
Sleep Apnea, Obstructive
Primary: Apnea-Hypopnea Index — 38.7; 28.5 events/hour
N/A N=270 Self-Management of Continuous Positive Airway Pressure Settings
Obstructive Sleep Apnea
Primary: Treatment Adherence — 2.1; 2.2 Hours per night
N/A N=10 SleepFlexTM Treatment of Obstructive Sleep Apnea
Obstructive Sleep Apnea
Primary: Number of Participants With Freedom From SleepFlex-related Serious Adverse Events — 10 Participants
N/A N=54 Diagnosis and Treatment of Sleep Apnea in the Acute Exacerbation of Heart Failure
Sleep Apnea · Heart Failure
Primary: Left Ventricular Ejection Fraction Improvement — 4.5; -.3 percent change
N/A N=56 Radiofrequency Ablation for Multi-level Obstructive Sleep Apnea: A Single-arm, Multicenter Study
Apnea, Sleep
Primary: Mean Apnea Hypopnea Index (AHI) at 6 Months Post-baseline — 9.86 No. of apneas/hypopneas per h of sleep
N/A N=169 Sleep Apnea Intervention for Cardiovascular Disease Reduction
Obstructive Sleep Apnea
Primary: Change From Baseline in 24-hour Blood Pressure at Months 6 and 12 by Pooled Arms — 1.82; 1.06; 0.59; -0.73 mmHg
N/A N=42 A Randomized Cross Over Trial of Two Treatments for Sleep Apnea in Veterans With Post-Traumatic Stress Disorder
Obstructive Sleep Apnea
Primary: Residual Apnea Hypopnea Index — 3.9; 26.3 events per hour — p=<0.001
Phase 2 N=20 Combination Drug-Therapy for Patients With Untreated Obstructive Sleep Apnea
OSA · Obstructive Sleep Apnea
Primary: Apnea Hypopnea Index (AHI) — 17.1; 32.7; 26; 23.6 events/hour of sleep
N/A N=17 Etiology of Sleep Apnea-related Hyperaldosteronism - BP Treatment
Obstructive Sleep Apnea · Resistant Hypertension · Hyperaldosteronism
Primary: Severity of Obstructive Sleep Apnea — -18.3; 7.0 events/hour
Phase 2 N=50 Effects of Treatment of Sleep Apnea on Metabolic Syndrome
Impaired Glucose Tolerance · Obstructive Sleep Apnea
Primary: Number of Subjects With Normalization of Impaired Glucose Tolerance (IGT) — 7; 5 subjects — p=0.57
N/A N=62 Trial on Oral Appliance Design for Improving Upper Airway Function and Sleep Quality
Obstructive Sleep Apnea
Primary: Respiratory Event Index (REI) at T2 — 12.8; 21.1; 9.3; 13.1 number of events per hour — p=0.152
N/A N=25 Continuous Positive Airway Pressure (CPAP), Oral Appliance and Physical Exercise in the Obstructive Sleep Apnea
Obstructive Sleep Apnea
Primary: Objective Sleep Parameters
Phase 3 N=280 Improving Obstructive Sleep Apnea Management Via Wireless Telemonitoring
Sleep Apnea Syndromes
Primary: Nightly CPAP Adherence — 3.7; 3.7; 3.7; 3.2 hours per night — p=0.50
N/A N=63 Hypoglossal Nerve Stimulation on Cardiovascular Outcomes
Obstructive Sleep Apnea
Primary: Mean 24-Hour Systolic Ambulatory Blood Pressure Values — 122.8; 123.0 mmHg
N/A N=28 Comparison of Two Techniques of Combination Therapy for Treatment of Obstructive Sleep Apnea (OSA)
Treatment for Obstructive Sleep Apnea
Primary: Apnea-Hypopnea Index — 4.1; 3.6 episodes/hour
N/A N=32 Auto Continuous Positive Airway Pressure (CPAP) Based Energy Spectrum Analysis of Flow for Treatment of Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS)
Sleep Apnea, Obstructive
Primary: Apnea Hypopnea Index (AHI) — 2.4 events per hour
N/A N=25 Servo-Ventilation In-lab PSG Evaluation
Sleep Apnea Syndromes
Primary: Average Apnea Hypopnea Index Among Different Polysomnography Devices. — 18.4; 25.4; 24.1; 19.2 events per hour
Phase 2 N=23 Using Telemedicine to Improve Veteran Sleep Apnea Care
Sleep Apnea Syndromes
Primary: Treatment Adherence — 3.4; 3.6 hours/night
N/A N=156 Continuous Positive Airway Pressure (PAP) Titration and Treatment Versus Auto-adjusting PAP Treatment for Sleep Apnea
Obstructive Sleep Apnea
Primary: Positive Airway Pressure Adherence (Nightly Use of Treatment) — 3.99; 4.45 hours — p== 0.27
N/A N=29 Effects of CPAP on Diet, Physical Activity, and Cardiovascular Risk
Sleep Apnea Syndromes
Primary: Fat Mass (% of Total Body Mass) — 40.0; 37.7; 38.7; 38.6 percentage of total body mass
Phase 3 N=169 Telemedicine Interventions for Obstructive Sleep Apnea (OSA)
Sleep Apnea
Primary: Change Over 6 Months in Epworth Sleepiness Scale Score — -0.23; -1.05; 0.43; -2.62 units on a scale
Phase 2 N=13 DAW1033B2 in Obstructive Sleep Apnea
Obstructive Sleep Apnea (OSA)
Primary: Apnea Hypopnea Index (AHI, Events/Hour of Sleep) — 33; 20.4 events/hour of sleep — p=0.47
Phase 3 N=225 Diagnosis and Treatment of Sleep Apnea in Cerebrovascular Disease
Obstructive Sleep Apnea · Stroke · Transient Ischemic Attack
Primary: Sleep Apnea Diagnosis Rate — 58; 5 participants